02/19/2026
“ARMMS-T2D is the largest and longest study comparing metabolic surgery to medical therapy for type 2 diabetes, and these results send a clear message: surgery delivers durable benefits in glycemic control and weight loss regardless of a patient’s socioeconomic background,” said Dr. John Kirwan, Director of the Integrated Physiology and Molecular Medicine Laboratory at Pennington Biomedical Research Center. “As a consortium, we’ve now shown across 12 years of follow-up that metabolic surgery can change the trajectory of this disease for diverse patient populations. That’s exactly the kind of evidence clinicians and patients need to make confident treatment decisions.” To view the full article, visit https://www.pbrc.edu/news/media/2026/joslin.aspx